Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Transcript

1. #1prepared remarks

   EX-99.1 2 abt-2026q2xexhibitx991.htm EX-99.1

2. #2prepared remarks

   Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

3. #3prepared remarks

   – Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent – Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 – Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 – Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58 – Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases

4. #4prepared remarks

   ABBOTT PARK, Ill., July 16, 2026 — Abbott today announced financial results for the second quarter ended June 30, 2026.

5. #5prepared remarks

   • Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis. • Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items. • Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 . • Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58. • In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation. • In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios. • In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the man…

6. #6Robert B. Ford · chairman and chief executive officer, Abbott

   Our second-quarter results reflect the momentum we are building,

7. #7prepared remarks

   Comparable sales growth: Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

8. #8prepared remarks

   Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

9. #9prepared remarks

   Second Quarter 2026 Results (2Q26) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Sales 2Q26 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established Pharmaceuticals | | Medical Devices | U.S. | 5,216 | | | 871 | | | 1,660 | | | — | | | 2,680 | | International | 7,377 | | | 1,273 | | | 1,432 | | | 1,499 | | | 3,173 | | Total reported | 12,593 | | | 2,144 | | | 3,092 | | | 1,499 | | | 5,853 | |

10. #10prepared remarks

    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | % Change vs. 2Q25 | | | | | | | | | | U.S. | 22.0 | | | (9.0) | | | 104.8 | | | n/a | | 7.0 | | International | 7.5 | | | 1.4 | | | 5.1 | | | 8.4 | | | 10.7 | | Total reported | 13.0 | | | (3.1) | | | 42.3 | | | 8.4 | | | 9.0 | | Total reported excl. foreign exchange impact | 12.2 | | | (3.6) | | | 41.3 | | | 8.7 | | | 7.9 | | | | | | | | | | | | Comparable sales growth | 4.8 | | | (3.6) | | | 2.9 | | | 8.7 | | | 8.4 | | | | | | | | | | | | U.S. | 3.5 | | | (9.0) | | | 4.0 | | | n/a | | 8.0 | | International | 5.8 | | | 0.6 | | | 1.6 | | | 8.7 | | | 8.7 | |

11. #11prepared remarks

    First Half 2026 Results (1H26) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Sales 1H26 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established Pharmaceuticals | | Medical Devices | U.S. | 9,490 | | | 1,715 | | | 2,565 | | | — | | | 5,203 | | International | 14,267 | | | 2,446 | | | 2,707 | | | 2,925 | | | 6,189 | | Total reported | 23,757 | | | 4,161 | | | 5,272 | | | 2,925 | | | 11,392 | |

12. #12prepared remarks

    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | % Change vs. 1H25 | | | | | | | | | | U.S. | 12.4 | | | (10.3) | | | 52.5 | | | n/a | | 7.4 | | International | 9.3 | | | — | | | 6.4 | | | 10.7 | | | 14.2 | | Total reported | 10.5 | | | (4.5) | | | 24.7 | | | 10.7 | | | 11.0 | | Total reported excl. foreign exchange impact | 8.2 | | | (5.6) | | | 22.4 | | | 8.9 | | | 8.0 | | Comparable sales growth | 4.3 | | | (5.6) | | | 2.4 | | | 8.9 | | | 8.4 | | | | | | | | | | | | U.S. | 3.0 | | | (10.3) | | | 3.0 | | | n/a | | 8.3 | | International | 5.3 | | | (1.9) | | | 1.6 | | | 8.9 | | | 8.5 | |

13. #13prepared remarks

    Refer to pages 16 and 17 for a reconciliation of comparable sales growth.

14. #14prepared remarks

    | | | | | | | | | | | | | | | | | | Sales 2Q26 ($ in millions) | Total | | Pediatric | | Adult | U.S. | 871 | | | 525 | | | 346 | | International | 1,273 | | | 500 | | | 773 | | Total reported | 2,144 | | | 1,025 | | | 1,119 | |

15. #15prepared remarks

    | | | | | | | | | | | | | | | | | | % Change vs. 2Q25 | | | | | | U.S. | (9.0) | | | (10.7) | | | (6.4) | | International | 1.4 | | | 7.3 | | | (2.0) | | Total reported | (3.1) | | | (2.7) | | | (3.4) | | | | | | | | | | | | | | Total reported excl. foreign exchange impact | (3.6) | | | (3.1) | | | (4.0) | | Comparable sales growth | (3.6) | | | (3.1) | | | (4.0) | | | | | | | | U.S. | (9.0) | | | (10.7) | | | (6.4) | | International | 0.6 | | | 6.4 | | | (2.8) | |

16. #16prepared remarks

    Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter. Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.

17. #17prepared remarks

    | | | | | | | | | | | | | | | | | | Sales 1H26 ($ in millions) | Total | | Pediatric | | Adult | U.S. | 1,715 | | | 1,036 | | | 679 | | International | 2,446 | | | 942 | | | 1,504 | | Total reported | 4,161 | | | 1,978 | | | 2,183 | |

18. #18prepared remarks

    | | | | | | | | | | | | | | | | | | % Change vs. 1H25 | | | | | | U.S. | (10.3) | | | (11.9) | | | (7.8) | | International | — | | | 2.4 | | | (1.5) | | Total reported | (4.5) | | | (5.6) | | | (3.5) | | Total reported excl. foreign exchange impact | (5.6) | | | (6.4) | | | (4.9) | | Comparable sales growth | (5.6) | | | (6.4) | | | (4.9) | | | | | | | | U.S. | (10.3) | | | (11.9) | | | (7.8) | | International | (1.9) | | | 0.7 | | | (3.5) | |

19. #19prepared remarks

    Second Quarter 2026 Results (2Q26) | | | | | | | | | | | | | | | | | | | | | | | | Sales 2Q26 ($ in millions) | Total | | Core Laboratory | | Cancer Diagnostics | | Rapid/Molecular Diagnostics | U.S. | 1,660 | | | 377 | | | 890 | | | 393 | | International | 1,432 | | | 1,041 | | | 29 | | | 362 | | Total reported | 3,092 | | | 1,418 | | | 919 | | | 755 | |

20. #20prepared remarks

    | | | | | | | | | | | | | | | | | | | | | | | | % Change vs. 2Q25 | | | | | | | | U.S. | 104.8 | | | 7.5 | | | n/a | | (14.5) | | International | 5.1 | | | 3.4 | | | n/a | | 2.0 | | Total reported | 42.3 | | | 4.4 | | | n/a | | (7.3) | | Total reported excl. foreign exchange impact | 41.3 | | | 3.2 | | | n/a | | (8.0) | | | | | | | | | | Comparable sales growth | 2.9 | | | 3.2 | | | 13.3 | | | (8.0) | | | | | | | | | | U.S. | 4.0 | | | 7.5 | | | 13.3 | | | (14.5) | | International | 1.6 | | | 1.7 | | | 13.8 | | | 0.5 | |

21. #21prepared remarks

    Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter. Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America. Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year. Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses.

22. #22prepared remarks

    First Half 2026 Results (1H26) | | | | | | | | | | | | | | | | | | | | | | | | Sales 1H26 ($ in millions) | Total | | Core Laboratory | | Cancer Diagnostics | | Rapid/Molecular Diagnostics | U.S. | 2,565 | | | 724 | | | 983 | | | 858 | | International | 2,707 | | | 1,966 | | | 32 | | | 709 | | Total reported | 5,272 | | | 2,690 | | | 1,015 | | | 1,567 | |

23. #23prepared remarks

    | | | | | | | | | | | | | | | | | | | | | | | | % Change vs. 1H25 | | | | | | | | U.S. | 52.5 | | | 6.0 | | | n/a | | (14.1) | | International | 6.4 | | | 6.1 | | | n/a | | 2.4 | | Total reported | 24.7 | | | 6.1 | | | n/a | | (7.4) | | Total reported excl. foreign exchange impact | 22.4 | | | 3.2 | | | n/a | | (8.8) | | | | | | | | | | Comparable sales growth | 2.4 | | | 3.2 | | | 13.3 | | | (8.8) | | | | | | | | | | U.S. | 3.0 | | | 6.0 | | | 13.2 | | | (14.1) | | International | 1.6 | | | 2.2 | | | 16.5 | | | (1.1) | |

24. #24prepared remarks

    *Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business. Refer to pages 16 and 17 for a reconciliation of comparable sales growth.

25. #25prepared remarks

    Second Quarter 2026 Results (2Q26) | | | | | | | | | | | | | | | | | | Sales 2Q26 ($ in millions) | Total | | Key Emerging Markets | | Other | U.S. | — | | | — | | | — | | International | 1,499 | | | 1,164 | | | 335 | | Total reported | 1,499 | | | 1,164 | | | 335 | |

26. #26prepared remarks

    | | | | | | | | | | | | | | | | | | % Change vs. 2Q25 | | | | | | U.S. | n/a | | n/a | | n/a | International | 8.4 | | | 9.8 | | | 3.7 | | Total reported | 8.4 | | | 9.8 | | | 3.7 | | | | | | | | Total reported excl. foreign exchange impact | 8.7 | | | 10.7 | | | 2.1 | | Comparable sales growth | 8.7 | | | 10.7 | | | 2.1 | | | | | | | | U.S. | n/a | | n/a | | n/a | International | 8.7 | | | 10.7 | | | 2.1 | |

27. #27prepared remarks

    Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.

28. #28prepared remarks

    Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.

29. #29prepared remarks

    First Half 2026 Results (1H26) | | | | | | | | | | | | | | | | | | Sales 1H26 ($ in millions) | Total | | Key Emerging Markets | | Other | U.S. | — | | | — | | | — | | International | 2,925 | | | 2,253 | | | 672 | | Total reported | 2,925 | | | 2,253 | | | 672 | |

30. #30prepared remarks

    | | | | | | | | | | | | | | | | | | % Change vs. 1H25 | | | | | | U.S. | n/a | | n/a | | n/a | International | 10.7 | | | 11.3 | | | 8.6 | | Total reported | 10.7 | | | 11.3 | | | 8.6 | | | | | | | | Total reported excl. foreign exchange impact | 8.9 | | | 10.1 | | | 4.9 | | Comparable sales growth | 8.9 | | | 10.1 | | | 4.9 | | | | | | | | U.S. | n/a | | n/a | | n/a | International | 8.9 | | | 10.1 | | | 4.9 | |